NDA 211964 · Supernus Pharms
Qelbree
Viloxazine Hydrochloride · Oral
NovelCDER novel approval, Apr 2, 2021: To treat attention deficit hyperactivity disorder
Last checked: Nov 20, 2026Latest source record: Jan 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Apr 2, 2021
Approved uses
2
Original approval plus efficacy supplements
Registered trials
15
8 Phase 3, 1 recruiting
FAERS reports
1,309
400 serious, 10 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS In clinical studies, higher rates of suicidal thoughts and behavior were reported in patients with ADHD treated with Qelbree than in patients treated with placebo . Closely monitor all Qelbree-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. In clinical trials, higher rates of suicidal thoughts and behavior were reported in patients treated with Qelbree than in patients treated with placebo. Closely monitor for worsening and emergence of suicidal thoughts and behaviors ( 5.1 ).
What it is approved for
From the label in effect Oct 5, 2026.
Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older. Qelbree is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older ( 1 )
Mechanism: The mechanism of action of viloxazine in the treatment of ADHD is unclear; however, it is thought to be through inhibiting the reuptake of norepinephrine.
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 29, 2022 Supplement 3 · Efficacy LabelLetter
- Apr 2, 2021 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
3 products under this application
- QELBREE · VILOXAZINE HYDROCHLORIDE EQ 200MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
- QELBREE · VILOXAZINE HYDROCHLORIDE EQ 100MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
- QELBREE · VILOXAZINE HYDROCHLORIDE EQ 150MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Viloxazine" as an intervention, any sponsor and status, largest first.
- Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)Pivotal-lookingActive, not recruiting
Supernus Pharmaceuticals, Inc.Industry
NCT02736656 · 1,400 participants (planned) · Start Feb 2, 2016 · Primary completion Dec 2026
Drug: SPN-812 · For: Attention-Deficit/Hyperactivity Disorder
Sites: Little Rock, Arkansas; Long Beach, California; Colorado Springs, Colorado · 16 sites in all
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHDPivotal-lookingCompleted
Supernus Pharmaceuticals, Inc.Industry
NCT03247530 · 477 participants · Start Oct 20, 2017 · Primary completion Sep 12, 2018
Drug: Placebo; 100mg SPN-812 and 1 more · For: ADHD
Sites: Dothan, Alabama; Hialeah, Florida; Meridian, Idaho · 7 sites in all
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHDPivotal-lookingCompleted
Supernus Pharmaceuticals, Inc.Industry
NCT04016779 · 374 participants · Start Nov 20, 2019 · Primary completion Oct 10, 2020
Drug: Placebo; SPN-812 · For: Attention-Deficit/Hyperactivity Disorder (ADHD)
Sites: Garden Grove, California; Los Alamitos, California; Newport Beach, California · 37 sites in all
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHDPivotal-lookingCompleted
Supernus Pharmaceuticals, Inc.Industry
NCT03247543 · 313 participants · Start Oct 31, 2017 · Primary completion Oct 17, 2018
Drug: Placebo; 200mg SPN-812 and 1 more · For: ADHD
Sites: Long Beach, California; Lauderhill, Florida; Orlando, Florida · 10 sites in all
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHDPivotal-lookingCompleted
Supernus Pharmaceuticals, Inc.Industry
NCT03247517 · 310 participants · Start Nov 2, 2017 · Primary completion Oct 17, 2018
Drug: Placebo; 200mg SPN-812 and 1 more · For: ADHD
Sites: Dothan, Alabama; Orange, California; Hialeah, Florida · 12 sites in all
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHDPivotal-lookingCompleted
Supernus Pharmaceuticals, Inc.Industry
NCT03247556 · 297 participants · Start Nov 20, 2017 · Primary completion Feb 14, 2019
Drug: Placebo; 400mg SPN-812 and 1 more · For: ADHD
Sites: Long Beach, California; Colorado Springs, Colorado; Bradenton, Florida · 14 sites in all
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHDPivotal-lookingRecruiting
Supernus Pharmaceuticals, Inc.Industry
NCT04781140 · 286 participants (planned) · Start Mar 19, 2024 · Primary completion Jan 2028
Drug: 100mg SPN-812; Placebo · For: Attention-Deficit/Hyperactivity Disorder
Sites: Saraland, Alabama; Fayetteville, Arkansas; Little Rock, Arkansas · 54 sites in all
- Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHDPivotal-lookingCompleted
Supernus Pharmaceuticals, Inc.Industry
NCT02633527 · 222 participants · Start Feb 1, 2016 · Primary completion Jul 25, 2016
Drug: Placebo; 100mg SPN-812 and 3 more · For: Attention-Deficit/Hyperactivity Disorder (ADHD)
Sites: Maitland, Florida
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache146
- vomiting132
- nausea130
- migraine124
- fatigue109
- insomnia109
- somnolence87
- drug ineffective82
- suicidal ideation82
- withdrawal syndrome57
- anxiety56
- product dose omission issue51
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 4 |
| 2020 | 1 |
| 2021 | 53 |
| 2022 | 215 |
| 2023 | 204 |
| 2024 | 186 |
| 2025 | 285 |
| 2026 | 361 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Qelbree (Viloxazine HCl)
2024 spending
$6.8M
Beneficiaries
3,232
11,851 claims
Per beneficiary
$2,103
$11.84 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $34,881 |
| 2022 | $1,045,765 |
| 2023 | $4,086,858 |
| 2024 | $6,796,781 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making.
Gosling CJ, Garcia-Argibay M, De Prisco M, et al. · BMJ 2025 · Systematic Review
- Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis.
Radonjik NV, Bellato A, Khoury NM, et al. · CNS Drugs 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
Farhat LC, Lannes A, Del Giovane C, et al. · Lancet Psychiatry 2025 · Systematic Review, Comparative Study
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
Nasser A, Hull JT, Chaturvedi SA, et al. · CNS Drugs 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Antidepressant drugs for narcolepsy.
Vignatelli L, D'Alessandro R, Candelise L · Cochrane Database Syst Rev 2008 · Systematic Review
- Population Pharmacokinetics of Viloxazine Extended-Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder.
Nasser A, Gomeni R, Wang Z, et al. · J Clin Pharmacol 2021 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Supernus Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.